Calibrate Secures $100M in Series B Funding to Revolutionize Weight Treatment

Calibrate, an innovative leader in the space of obesity treatment, is proud to announce its recent funding achievement, successfully raising $100 million to further its mission of transforming how weight is treated globally. As a pioneer in the clinician-guided and value-based outcomes model, Calibrate utilizes a holistic approach that integrates medication with profound behavioral change to enhance metabolic health. This groundbreaking methodology not only supports sustainable weight loss but also aims to minimize overall healthcare costs for employers and payers. The funding will be instrumental in scaling Calibrate’s offerings, expanding access to its cutting-edge programs, and investing in technology that supports patient engagement and adherence. Recognized by prestigious institutions, including the World Economic Forum’s Technology Pioneers and TIME’s Best Inventions, Calibrate has positioned itself at the forefront of healthcare innovation. With backing from prominent investors such as Madryn Asset Management and Redesign Health, the company is poised for significant growth as it addresses one of the most pressing health challenges of our time. As obesity rates continue to rise, effective solutions like Calibrate’s are needed more than ever, not only to improve individual health outcomes but also to drive systemic change in the way obesity is understood and treated. This funding will enable Calibrate to leverage its proven model and ultimately create a healthier future for millions.